Biogen Can't Block Mylan MS Drug Launch During IP Appeal
Law360 (July 30, 2020, 3:01 PM EDT) -- The Federal Circuit on Thursday paved the way for Mylan to launch its forthcoming generic version of Biogen's top-selling multiple sclerosis drug Tecfidera while Biogen appeals the invalidation of a patent covering the drug.
The court shot down Biogen International GmbH's request for an injunction that would have kept Mylan Pharmaceuticals Inc. off the market until the appeal is settled. The Federal Circuit outlined the factors it considered — including likelihood of success and irreparable harm — but did not include its analysis of them in the order.
"Without prejudicing the ultimate disposition of this case by a merits panel, we...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!